Moderna, Merck personalized mRNA melanoma vaccine cuts recurrence risk 42% in Phase 3
The individualized cancer vaccine pairing Moderna's mRNA with Merck's Keytruda is the first Phase 3 win for a personalized cancer therapy, though the data spark
Bioengineer.org · +15 outlets
FDA and CMS outline faster approval pathway for personalized gene therapies
The agencies detailed a quicker route to market for individualized rare disease gene therapies, a move rare disease advocates welcomed.
STAT · +3 outlets
Artiva shuts down after two patient deaths in autoimmune cell therapy trial
Artiva becomes the third company to report fatal events in an autoimmune cell therapy trial, following Novartis and Bristol Myers Squibb.
STAT · +9 outlets
Bristol Myers Squibb reports patient death in MS CAR-T trial, cause unclear
A patient who received BMS's zola-cel died 44 days later; the company says it wants to get the program back on track.
Biopharmadive · +14 outlets
Ferring to acquire IVF startup Gameto for up to $1.4B
The buyout gives Ferring rights to technology aimed at simplifying the lengthy in vitro fertilization process.
Biopharmadive · +4 outlets
Melbourne cancer therapy startup wins $2B deal with Japan's Astellas
The deal is one of the largest for an Australian cancer biotech and highlights Asian pharma's appetite for radiopharmaceutical and targeted oncology assets.
AFR · +1 outlets
FDA approves breakthrough drug for advanced pancreatic cancer
The approval adds a new option for a cancer with among the lowest survival rates.
University of Colorado Anschutz · +13 outlets
Roche's KRAS drug divarasib posts strong lung cancer data at ESMO
The data set was among the most impressive at ESMO, advancing Roche's position in the competitive KRAS field.
STAT · +9 outlets
Court rejects Novo Nordisk bid to block Lilly obesity drug ads
A federal judge ruled Novo failed to prove Lilly's superiority claims meaningfully harmed Wegovy sales.
Biopharmadive · +12 outlets
Incyte reports lasting tumor responses in pancreatic cancer at ESMO
The targeted drug, combined with chemotherapy, showed responses in a KRAS G12D race Incyte calls neck and neck with Revolution Medicines.
STAT · +6 outlets
Merck and Kelun's sac-TMT cuts death risk by a third in advanced endometrial cancer
The Phase 3 result supports the antibody-drug conjugate in a new tumor type.
STAT · +14 outlets
GSK's B7-H3 ADC cuts cancer risk 67% in Hansoh Phase 3 China trial
The data mark another step in GSK's return to oncology, where it could soon win approval for a sixth cancer drug.
STAT · +5 outlets
Arbutus wins FDA clearance to resume hepatitis B drug trials
The clearance lifts a clinical hold on the company's hepatitis B program.
MyChesCo · +3 outlets
Hengrui presents 64 studies at ESMO 2026, a record for a Chinese oncology company
The volume underscores the growing presence of Chinese drugmakers at major cancer meetings.
The Clinical Trial Vanguard · +4 outlets
Missouri AG warns Lilly over 340B data demands from hospitals
The warning is a sign more states are pushing back against drugmakers' conditions on discounted medicines.
STAT · +4 outlets
Nonprofit resurrects shelved gene therapy after UK startup Bloomsbury shuts down
Bloomsbury Genetic Therapies had dosed just one patient before closing; a nonprofit is now reviving its lead program.
STAT
Corxel to go public via SPAC with $300M and two weight loss drugs
Corxel becomes the latest GLP-1 and amylin-focused company to join the public markets.
Biopharmadive · +1 outlets
Pfizer's Talzenna plus Xtandi approved for earlier metastatic prostate cancer setting
The label expansion moves the combination earlier in the treatment sequence for metastatic prostate cancer.
Business Wire